Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …

Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …

Abstract Background Immune checkpoint therapies (ICTs) targeting the programmed cell
death-1 (PD1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes …

Background: The emergence of novel antiprogrammed cell death protein-1 (PD-1) inhibitors
in non-small cell lung cancers (NSCLC) has revolutionized the therapeutic landscape of this …

Background Second-line immunotherapy (IO) has shown an overall survival benefit.
However, only 18% to 20% of patients with advanced non–small-cell lung cancer (aNSCLC) …

The introduction of immune checkpoint inhibitors (ICI), as a novel treatment modality, has
transformed the field of oncology with unprecedented successes. However, the efficacy of …

Simple Summary The benefit of programmed death-1/programmed death ligand-1 (PD-1/PD-
L1) immunotherapy, particularly of nivolumab, pembrolizumab and atezolizumab, in the …

Background It has recently been suggested that concomitant medication may affect the
clinical outcome of patients treated with immune checkpoint inhibitors (ICIs). However, only …

Objectives Combined therapy should be invested for those patients who are refractory to first-
line therapy. Anti-angiogenic agents could enhance tumor immunity response. We designed …

Background: The prognostic nutritional index (PNI) is related to the prognosis of multiple
malignancies. This study investigated whether the PNI has prognostic value in advanced …